





This presentation will provide an overview of the role the gut microbiome in modulating systemic inflammation


Key topics:


- The role of gut dysbiosis and increased intestinal permeability in chronic low-grade inflammation
- A comparison of dietary interventions targeted towards modulating inflammation via the gut microbiome
























the for	All inflammatory disease begins with the (leaky) gut?	
570	Limited mechanistic insight to prove that it is the single unifying cause of specific inflammatory diseases	Limited repeatable and reliable measures of intestinal permeability
	Limited information on measure of who/ what is being translocated through these virtual barriers	The inflammatory response to the barrier injury is what is important and this can vary from person to person



























Key takeaways				
	N			
1	Different fibre sources available as part of a fibre rich diet - diversity at its best!			
2	Limited change in the microbiome in response to a high-fibre diet demonstrates resilience of the human microbiome over short time periods			
3	Single fibre sources/supplements may offer more insight into mechanistic pathways, helps assign functional attributes based on source and structure			
4	Knowledge of physiological effects associated with different fibres can be applied to whole food sources that may offer targeted health outcomes			
5	Individual variability in the response of the gut microbiota to different fibres and fibre combinations highlights importance of a personalised approach to maximise benefit			
23				


Section 3

## Fermented foods versus probiotic supplements



Effectiveness of probiotic supplementation Meta-analysis of RCTs on inflammatory diseases Reduced the inflammatory potential of the gut in IBD patients with mild-moderately active ulcerative colitis and patients already in remission a-Díaz et al., 2017 Improved symptoms of pain in patients. More randomized **Inflammatory Arthritis** controlled trials needed to determine optimal dosing and improve efficacy Zeng et al., 2022 Improved severity of AD however, strong evidence to support the **Atopic Dermatitis** effectiveness of the administration of probiotic supplements at a clinical level remains elusive Umborowati et al., 2022 Certain probiotic formulations more effective than others in improving Asthma asthma outcomes. Results are conflicting due to discrepancy in dosage, duration, unknown strains used Ciprandi et al., 2023 Metabolic syndrome Probiotic supplements improved specific anthropometric and biochemical outcomes among individuals with MetS however, not sufficient evidence to reduce overall health risks Dong et al., 2019 26


Based on in vitro & in vivo models					
Production of bioactive compounds (SCFAs) Bifidobacterium longum subsp, infantis 157F, L. reuteri, L. pentosus, L. rhamnosus I, L. paracasei subsp.	Maintenance of barrier integrity L. rhamnosus strain GG, L plantarum, Bifidobacterium dentium N8, Lactobacillus strains				
paracasei, <b>L. plantarum</b>	Immune meduletien /enti inflammeter /				
Bioconversion of substrates and biodegradation of toxins Bifidobacterium animalis subsp. lactis HN019, L. reuteri, Saccharomyces boulardii and Saccharomyces cerevisiae	Immune modulation/anti-inflammatory potential L. plantarum, Apilactobacillus kosoi 10HT, A. kunkeei JCM16173T, and A. apinorum JCM30765T				





<ul> <li><b>BASELINE FEATURES OF HOST MICROBIOME</b></li> <li>Stable engraftment of specific probiotics depend on individualised features of the host gut microbiome</li> <li>Example- oral administration of <i>B.longum</i> AH1206 persisted in the gut of 30% of individuals for 6 months</li> <li>Lower levels of <i>B.longum in the baseline gut – Darwin's naturalization hypothesis!</i></li> <li>Indicates the importance of considering baseline microbiome features for precise and personalized microbiome reconstitution</li> </ul>

Key takeaways				
	1 Both Fermented foods and supplements confer positive effects in modulating inflammatory profiles			
	2 Fewer studies have directly assessed the role of fermented foods on clinical health outcomes			
	3 Fermented foods consists of a heterogenous mixture of microbes and other actives offering a synergetic effect over shorter durations			
	4 Probiotic properties are both strain and disease-specific need for personalisation!			
	5 Considering the functional capacity of probiotics, a given preparation could not be all-encompassing in a given condition			


Emergence of synbiotic interventions			
Products in which the prebiotic compound(s) selectively favour the probiotic organism(s)	<ul> <li>Complementary Synbiotics</li> <li>Synergistic Synbiotics</li> <li>More than just a commercial formulation</li> <li>Effective in disease &amp; healthy states</li> </ul>		
	Synbiotic effect based on microbial enterotypes	(Kazemi et al. 2020)	
31		(	











References

